Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 9/20 | 1.00 |
| ▸ | DAO | P14920 | 2/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.55 |
| ▸ | LIG1 | P18858 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247382 | 1.00 | CES1 (1.00) | CES1DAONSD2BCHEDNMT1 | |
| Methane SCHEMBL28522370 | 0.98 | CES1 (0.96) | CES1DAONSD2BCHEDNMT1 | |
| SCHEMBL25112387 | 0.87 | CES1 (0.77) | CES1DAONSD2BCHEDNMT1 | |
| SCHEMBL28552839 | 0.83 | CES1 (0.71) | CES1DAONSD2BCHEDNMT1 | |
| SCHEMBL19855787 | 0.83 | CES1 (0.71) | CES1DAONSD2BCHEDNMT1 | |
| SCHEMBL5988948 | 0.76 | CES1 (0.61) | CES1DAONSD2BCHEDNMT1 | |
| SCHEMBL11530748 | 0.76 | CES1 (0.61) | CES1DAONSD2BCHEDNMT1 | |
| SCHEMBL505703 | 0.75 | CES1 (0.60) | CES1DAONSD2BCHEDNMT1 | |
| SCHEMBL6845708 | 0.75 | CES1 (0.60) | CES1DAONSD2BCHEDNMT1 | |
| SCHEMBL3088689 | 0.75 | DAO (1.00) | CES1DAONSD2BCHELIG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111187233-B | Polysubstituted benzothiazole and derivative and synthesis method thereof | 湘潭大学 | 2023-05-30 | — | — | CN | claimed |
| CN-115974759-B | Compound with antibacterial use | 中国医学科学院药物研究所 | 2025-06-17 | — | — | CN | disclosed |
| US-20230234937-A1 | INDENOAZANAPHTHALENES | MERCK PATENT GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
| CN-111511719-B | Novel quinoline compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-111187233-B | Polysubstituted benzothiazole and derivative and synthesis method thereof | 湘潭大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
| CN-114728998-A | Sulfonamide compounds targeting CD73 and adenosine receptors | 奥瑞基尼探索技术有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4021895-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| CN-114502538-A | Substituted 3, 4-dihydroquinazolines for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-110964018-B | Indole derivative and application thereof | 华侨大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-114144401-A | Novel quinazoline compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234937-A1 | INDENOAZANAPHTHALENES | NQO1, CYP2D6, SQOR | CES1 1660/4885DAO 1351/4885NSD2 1823/4885 |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, MPST, CRAT | CES1 217/4885DAO 1701/4885NSD2 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.